p53 - Based cyclotherapy: exploiting the «guardian of the genome» to protect normal cells from
cytotoxic therapy.
: We conclude that treatment of triple negative breast cancers with growth hormone - releasing hormone antagonists reduces tumor growth and potentiates the effects of
cytotoxic therapy by nullifying drug resistance.
Evaluation of Poly - Mechanistic Antiangiogenic Combinations to Enhance
Cytotoxic Therapy Response in Pancreatic Cancer.
Nintedanib, a triple angiokinase inhibitor, enhances
cytotoxic therapy response in pancreatic cancer.
«But in the body, within the microenvironment they create, they somehow manage to resist elimination even by our most
cytotoxic therapies.»
Not exact matches
No targeted
therapy has been approved for noninflammatory and inflammatory triple - negative breast cancer tumors, and the standard of
therapy for these tumors is a combination of conventional
cytotoxic chemotherapeutic agents.
In the sensitive tumor models, the ability of anti —
cytotoxic T lymphocyte — associated protein 4 or anti — programmed cell death 1
therapy to increase vessel perfusion strongly correlated with its antitumor efficacy.
«The
cytotoxic chemotherapy can first kill some cancer cells and enhance the sensitivity of the tumour toward ICB
therapy, which then stimulates the effectiveness of the ICB
therapy,» said co-author Gianpietro Dotti, PhD, professor of microbiology and immunology at the UNC School of Medicine and member of the UNC Lineberger Comprehensive Cancer Center.
Thus, current efforts have focused on finding novel targets to improve
cytotoxic T cell activity that will augment existing
therapies.
Receptor - targeted
therapy of human experimental urinary bladder cancers with
cytotoxic LH - RH analog AN152 [AEZS - 108].
This condition may be present at birth, or it may be caused by certain infections (such as human immunodeficiency virus or HIV), or by certain cancer
therapies, such as cancer - cell killing (
cytotoxic) drugs, radiation, and bone marrow transplantation.
Low - dose chemotherapy, radiation, or targeted
therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the
cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.
And radiation
therapy causes what's called a
cytotoxic effect on those.
Worked in a Phase I / II clinical trials research laboratory that focuses on the development of antigen - specific
cytotoxic T - lymphocytes for adoptive cellular immune
therapies in children and adults
Surgery, radiation, and
cytotoxic / targeted
therapies are common treatment approaches in most advanced cancers.